english Archives - 29 중 4 번째 페이지

Onconic Therapeutics Bets Its Future on Homegrown Drugs…from GERD to Pancreatic Cancer

[photo=Onconic Therapeutics] Onconic Therapeutics’ first domestically developed drug, Zacubo, is rapidly growing in Korea and has now entered the regulatory process in China, the world’s largest gastroesophageal reflux disease (GERD)…

Cheon Okhyeon

2025-08-19

Daewoong’s Microneedle Patch Hits 80% of Injection Efficiency

A microneedle patch for obesity treatment, delivering drug absorption rates close to those of injections, has moved a step closer to commercialization. Daewoong Pharmaceutical (Co-CEOs Park Seong-su and Lee Chang-jae)…

Cheon Okhyeon

2025-08-13

Celltrion Wins Successive Bids in Italian Regional Drug Tenders

Celltrion is expanding its presence in Italy as its autoimmune disease treatments and cancer therapies continue to secure wins in regional government tenders. Celltrion’s Italian subsidiary announced on August 12…

Cheon Okhyeon

2025-08-12

K-CAB Surge and Vaccine Distribution Put HK inno.N on the Verge of ₩1 Trillion in Annual Sales

HK inno.N is closing in on its first-ever annual sales of ₩1 trillion. According to financial data provider FnGuide on August 11, the company’s 2025 revenue is projected at ₩1.0969…

Cheon Okhyeon

2025-08-11

LG Chem Sells Aesthetics Business to Focus on Oncology

LG Chem has sold its aesthetics business, including its hyaluronic acid (HA) fillers, for approximately KRW 200 billion (USD 144 million), shifting its strategic focus to oncology drug development. On…

Cheon Okhyeon

2025-08-07

Hugel Reports Record-Breaking Q2 Results Fueled by Toxin and Filler Exports

Hugel posted its highest-ever quarterly earnings in the second quarter of 2025, driven by strong global demand for its botulinum toxin and hyaluronic acid (HA) filler products. The South Korea-based…

Cheon Okhyeon

2025-08-06

Celltrion Named Preferred Bidder for U.S. Plant to Address Tariff Risks

Celltrion has taken a major step to resolve tariff risks from the U.S. by pursuing the acquisition of a local production facility—a bold investment move. If the deal is finalized,…

Cheon Okhyeon

2025-07-29

Alteogen’s Eylea Biosimilar Clears EU Hurdle

Alteogen has cleared a major regulatory hurdle in its bid to enter the European biosimilar market. The Korean biopharmaceutical company announced on July 28 that the Committee for Medicinal Products…

Won Jonghyuck

2025-07-28

Daewoong Pharmaceutical Enters Biosimilar Race with Dupixent Candidate as First Pipeline

Daewoong Pharmaceutical is making a full-fledged entry into the biosimilar business as a new growth driver, bringing on board Dr. Seung-Seo Hong, a key figure in Celltrion’s biosimilar development. As…

Cheon Okhyeon

2025-07-22

Celltrion Reports Record Q2 Profit on Strong Sales of High-Margin Drugs

Celltrion achieved its highest-ever quarterly performance in the second quarter of 2025, fueled by robust sales of high-margin new products. On July 21, Celltrion announced provisional consolidated results for Q2…

Cheon Okhyeon

2025-07-21